The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     
1 pt

Opinion on  Valeant Pharmaceuticals International (VRX)     Sector: Healthcare  >  Industry: Biotechnology & Drugs
Valeant's Promising Epilepsy Drug

Jun 03, 2009 06:53 PM GMT
Return Risk
+12.48% LOW
Sr. Analyst

Valeant has a promising epilepsy drug, retigabine, that is significantly undervalued by Wall Street. Healey sees the stock doubling to $40 to $50 a share in the next 12 to 18 months - Joseph Healey, HEALTHCOR


VRX:  This call was made on 06/03/09 @ $23.05
Rating:   Positive   $23.05 (06/03/09)
Closed:   07/30/2009 @ $25.19 (+9.28% in 57 days)
Target:   $35.00 (+51.84%) in > one year


Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 21.10 +35.25% 368
2 18.14 +70.90% 206
3 17.66 +25.78% 53
4 13.47 +14.32% 60
5 12.13 +69.23% 34


POPULAR STOCKS
Symbol Company Name Sentiment

TODAY'S HEADLINES

TODAY'S TOP PICKS

 
Valeant Pharmaceuticals International (VRX)
   SocialPicks Sentiment:   

   This Quarter's Sentiment:
All:
50.0%
Top:
0.0%




Latest Picks by jgarner3999
Symbol SP Sentiment Rating Return Since
RIMM Positive -14.47% 10/05/09
C Positive -10.38% 09/14/09
F Positive +0.00% 09/04/09
TBT Positive +1.59% 08/27/09
ETFC Positive +2.05% 07/30/09

View All >
   




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch